<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Such ", fill: "#cd853f"},
{source: "3: Such ", target: "3: factors among others may", fill: "#cd853f"},
{source: "3: factors among others may", target: "3: financial condition", fill: "#cd853f"},
{source: "3: financial condition", target: "3: operations", fill: "#cd853f"},
{source: "3: Such ", target: "7: acquisitions", fill: "#5f9ea0"},
{source: "7: acquisitions", target: "7: Novacept ", fill: "#5f9ea0"},
{source: "7: acquisitions", target: "9: acquisitions", fill: "#f4c430"},
{source: "9: acquisitions", target: "9: manufacture", fill: "#f4c430"},
{source: "9: manufacture", target: "9: worldwide consolidated net sales", fill: "#f4c430"},
{source: "9: worldwide consolidated net sales", target: "9: December ", fill: "#f4c430"},
{source: "9: acquisitions", target: "11: successfully", fill: "#708090"},
{source: "11: successfully", target: "11: commercialize", fill: "#708090"},
{source: "11: commercialize", target: "11: profits may", fill: "#708090"},
{source: "11: profits may", target: "11: materially impaired", fill: "#708090"},
{source: "11: successfully", target: "39: breast surgeons radiation oncologists", fill: "#79443b"},
{source: "39: breast surgeons radiation oncologists", target: "39: MammoSite System ", fill: "#79443b"},
{source: "39: MammoSite System ", target: "39: preferred treatment", fill: "#79443b"},
{source: "39: preferred treatment", target: "39: intended benefits", fill: "#79443b"},
{source: "39: intended benefits", target: "39: acquisition", fill: "#79443b"},
{source: "39: acquisition", target: "39: market price", fill: "#79443b"},
{source: "39: market price", target: "39: common stock could decline", fill: "#79443b"},
{source: "39: breast surgeons radiation oncologists", target: "START_HERE", fill: "#79443b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_RTO_districts_in_Kerala">List of RTO districts in Kerala</a></td>
      <td>\n== Regional Transport Offices ==\n\n\n== Sub Regional Transport Offices ==\n\n\n== Future Sub Regional Transport Offices ==\nGovernment of Kerala has repeatedly intimated multiple legislative members that there are no plans to setup any new RTOs/SRTOs in Kerala unless the financial condition of Kerala improves.\n\n\n== References ==\n\nOfficial list of Regional Transport Offices\nOfficial list of Sub Regional Transport Offices\n\n\n== External links ==\nhttps://www.mvd.kerala.gov.in (Link to Kerala Motor Vehicles Department.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Meta_Platforms">List of mergers and acquisitions by Meta Platforms</a></td>
      <td>Meta Platforms (formerly Facebook, Inc.) is a technology company that has acquired 91 other companies, including WhatsApp. The WhatsApp acquisition closed at a steep $16 billion; more than $40 per user of the platform.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Alphabet">List of mergers and acquisitions by Alphabet</a></td>
      <td>Google is a computer software and a web search engine company that acquired, on average, more than one company per week in 2010 and 2011. The table below is an incomplete list of acquisitions, with each acquisition listed being for the respective company in its entirety, unless otherwise specified.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ben_Ashkenazy">Ben Ashkenazy</a></td>
      <td>Ben Ashkenazy (born 1968/69) is an American billionaire real estate developer. He is the founder, CEO, and majority owner of Ashkenazy Acquisition Corporation, which has a $12 billion property portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition">Language acquisition</a></td>
      <td>Language acquisition is the process by which humans acquire the capacity to perceive and comprehend language (in other words, gain the ability to be aware of language and to understand it), as well as to produce and use words and sentences to communicate.\nLanguage acquisition involves structures, rules and representation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Success">Success</a></td>
      <td>Success is the state or condition of meeting a defined range of expectations. It may be viewed as the opposite of failure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Breast_cancer_management">Breast cancer management</a></td>
      <td>Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shyam_Benegal">Shyam Benegal</a></td>
      <td>Shyam Benegal (born 14 December 1934) is an Indian film director, screenwriter and documentary filmmaker. Often regarded as the pioneer of parallel cinema, He is widely considered as one of the greatest filmmakers post 1970s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_NetBeans-based_software">List of NetBeans-based software</a></td>
      <td>The NetBeans platform can be extended by adding different plug-ins, for example:\n\nOracle Solaris Studio, formerly known as Sun Studio, is an IDE based on NetBeans, focusing on the programming languages C, C++, and Fortran.\nPoseidon for UML\nFantom IDE is an IDE for the Fantom language, based on the NetBeans Platform.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second_Italo-Ethiopian_War">Second Italo-Ethiopian War</a></td>
      <td>The Second Italo-Ethiopian War, also referred to as the Second Italo-Abyssinian War, was a war of aggression which was fought between Italy and Ethiopia from October 1935 to February 1937. In Ethiopia it is often referred to simply as the Italian Invasion (Amharic: ጣልያን ወረራ), and in Italy as the Ethiopian War (Italian: Guerra d'Etiopia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intraoperative_electron_radiation_therapy">Intraoperative electron radiation therapy</a></td>
      <td>Intraoperative electron radiation therapy is the application of electron radiation directly to the residual tumor or tumor bed during cancer surgery. Electron beams are useful for intraoperative radiation treatment because, depending on the electron energy, the dose falls off rapidly behind the target site, therefore sparing underlying healthy tissue.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CYTYC CORP      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>The following factors, among others, could cause actual results to differ     <font color="blue"><font color="blue">materially</font> from</font> those contained in forward-looking statements made in this     report  and  <font color="blue">presented elsewhere by <font color="blue">management</font> from</font> time to time</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>factors, among others, may have a material adverse effect upon our business,     <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The following discussion of our <font color="blue">risk factors should</font> be read in <font color="blue">conjunction</font>     with  the <font color="blue">consolidated financial statements</font> and related notes included     herein</td>
    </tr>
    <tr>
      <td>Because of these and other factors, past financial performance     should not be considered an <font color="blue">indication</font> of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend principally on</font> the sale of <font color="blue">three product lines</font></td>
    </tr>
    <tr>
      <td>Prior  to  our  <font color="blue"><font color="blue">acquisition</font>s</font>  of  <font color="blue">Novacept  </font>in  March 2004 and Proxima     Therapeutics,  Inc</td>
    </tr>
    <tr>
      <td>(“Proxima”) in March 2005, we <font color="blue">derived most</font> of our     <font color="blue">revenues from sales</font> of our ThinPrep processor, filters and other disposable     supplies  for  use  in  <font color="blue">gynecological</font>  and  non-<font color="blue">gynecological</font>  testing     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>As a result of the Novacept and Proxima <font color="blue"><font color="blue">acquisition</font>s</font>, we now     <font color="blue">manufacture</font> and market the NovaSure, MammoSite and <font color="blue">GliaSite System</font>s, which     represented  29prca of <font color="blue">worldwide consolidated net sales</font> in the year ended     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Nevertheless, we <font color="blue">still rely heavily on sales</font> of our     ThinPrep products to generate a <font color="blue">significant</font> portion of our net sales and     earnings</td>
    </tr>
    <tr>
      <td>If  we  are  unable to continue to <font color="blue">successfully</font> develop and     <font color="blue">commercialize</font>  our  current  <font color="blue">products as well</font> as other new or improved     products, our business, sales and <font color="blue">profits may</font> be <font color="blue"><font color="blue">materially</font> impaired</font></td>
    </tr>
    <tr>
      <td>In addition, in October 2003, an article in the <font color="blue">New England Journal </font>of     Medicine suggested that the <font color="blue">interval between screenings</font> for <font color="blue">cervical cancer</font>     could be <font color="blue">extended from one year</font> to <font color="blue">three years</font> for women over 30 who have     had <font color="blue">consistently negative</font> results <font color="blue">from previous screenings</font></td>
    </tr>
    <tr>
      <td>If screening     periods are <font color="blue">extended as</font> suggested, <font color="blue">aggregate demand</font> for testing is likely to     decrease and if we are unable to <font color="blue">successfully</font> develop <font color="blue"><font color="blue">additional</font> products</font>,     our business may be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may be     required to obtain FDA approval and <font color="blue">secure adequate <font color="blue">reimbursement</font> from</font>     insurance  companies and other third-party payors for any other new or     <font color="blue">improved products</font> that we are able to develop or acquire, and we may not be     able to do so</td>
    </tr>
    <tr>
      <td>Our sales are dependent on third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Widespread </font>adoption of our ThinPrep, ThinPrep Imaging, NovaSure, our newly     acquired MammoSite and <font color="blue">GliaSite System</font>s, and the <font color="blue">FirstCyte Breast Test </font>in     <font color="blue">the <font color="blue">United States </font></font>and other countries is <font color="blue">dependent upon</font> the ability of     healthcare providers and <font color="blue">laboratories</font> to <font color="blue">secure adequate <font color="blue">reimbursement</font> from</font>     third-party  payors  such  as  private  insurance  plans, <font color="blue">managed care</font>     <font color="blue">organizations</font>, <font color="blue">Medicare and Medicaid </font>and foreign <font color="blue">governmental</font> healthcare     agencies</td>
    </tr>
    <tr>
      <td>Although a majority of <font color="blue">managed care</font> <font color="blue">organizations</font> in the United     States have added the <font color="blue">ThinPrep Pap Test </font>to their coverage and the NovaSure,     MammoSite and GliaSite procedures are <font color="blue">reimbursed by</font> many <font color="blue">private healthcare</font>     insurance and <font color="blue">managed care</font> payors, we <font color="blue">cannot guarantee</font> that <font color="blue">reimbursement</font>     <font color="blue">will increase</font> or continue to be available, or that <font color="blue">reimbursement</font> levels will     be adequate to <font color="blue">enable healthcare providers</font> and clinical                                           17     ______________________________________________________________________    [40]Table of <font color="blue">Contents         </font><font color="blue">laboratories</font> in <font color="blue">the <font color="blue">United States </font></font>and other countries to use our products     instead of <font color="blue"><font color="blue">conventional</font> methods</font> or existing therapies, such as whole breast     <font color="blue">irradiation</font>  and  <font color="blue">brachytherapy</font>,  or  the products of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>and healthcare payment systems in <font color="blue">international</font> markets vary     <font color="blue">significant</font>ly by country and include both government-sponsored healthcare     and private insurance</td>
    </tr>
    <tr>
      <td>There can be no assurance that third-party payors     will  provide  or  continue to <font color="blue">provide such coverage</font>, that third-party     <font color="blue">reimbursement</font> will be made <font color="blue">available at</font> an <font color="blue">adequate level</font>, if at all, for     our products under any such overseas <font color="blue">reimbursement</font> system or that healthcare     providers or clinical <font color="blue">laboratories</font> will use our products in lieu of other     methods</td>
    </tr>
    <tr>
      <td>We also will be required to secure adequate <font color="blue">reimbursement</font> for any     new  products  we  develop or acquire, and we may not be able to do so     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> a <font color="blue">relatively</font> small number of large <font color="blue">clinical laboratory</font>     customers in <font color="blue">the <font color="blue">United States </font></font>for a <font color="blue">significant</font> portion of our sales of the     <font color="blue">ThinPrep System</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> a <font color="blue">relatively</font> small number of large <font color="blue">clinical laboratory</font>     customers in <font color="blue">the <font color="blue">United States </font></font>for a <font color="blue">significant</font> portion of our sales of the     <font color="blue">ThinPrep System</font>, and our business may <font color="blue">materially</font> suffer if we are unable to     increase  sales  to, or maintain our <font color="blue">pricing levels with</font>, our existing     customers and <font color="blue">establish new customers both within</font> and outside the United     States</td>
    </tr>
    <tr>
      <td>Due in part to a <font color="blue">trend toward consolidation</font> of clinical <font color="blue">laboratories</font>     in  recent  years  and  the <font color="blue">relative size</font> of the largest <font color="blue">United States </font>    <font color="blue">laboratories</font>, it is likely that a <font color="blue">significant</font> portion of <font color="blue">ThinPrep System</font>     <font color="blue">sales will continue</font> to be <font color="blue">concentrated among</font> a <font color="blue">relatively</font> small number of     large clinical <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">faces intense competition from</font> other companies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products face direct competition from</font> a number of publicly-traded and     privately-held companies</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> are large companies that     enjoy <font color="blue">significant</font> <font color="blue">competitive</font> advantages over us, including:           •   <font color="blue">significant</font>ly greater name <font color="blue">recognition</font>;           •   established <font color="blue">distribution</font> networks;           •   <font color="blue">additional</font> lines of products, and the ability to <font color="blue">offer rebates</font> or     <font color="blue">bundle products</font> to <font color="blue">offer discounts</font> or <font color="blue">incentives</font> to gain <font color="blue">competitive</font>     advantage;           •   <font color="blue">greater resources</font> for product <font color="blue">development</font>, sales and marketing; and           •   well-established products for <font color="blue">procedures such as</font> the radical     <font color="blue">mastectomy</font> or <font color="blue">traditional radiation therapy</font></td>
    </tr>
    <tr>
      <td>The markets we sell in are intensely <font color="blue">competitive</font>, subject to rapid change     and <font color="blue">significant</font>ly <font color="blue">affected by</font> new product <font color="blue"><font color="blue">introduction</font>s</font> and other market     <font color="blue">activities</font> of <font color="blue">industry participants</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies may</font> develop products     that  are superior to ours or <font color="blue">less expensive</font>, or both</td>
    </tr>
    <tr>
      <td><font color="blue">Improvements </font>in     existing  <font color="blue">competitive</font> products or the <font color="blue"><font color="blue">introduction</font>s</font> of new <font color="blue">competitive</font>     <font color="blue">products may reduce</font> our ability to compete for sales, particularly if those     <font color="blue">competitive</font> products <font color="blue">demonstrate</font> better safety or <font color="blue">effectiveness</font>, clinical     results, ease of use or <font color="blue">lower costs</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, FDA approval and     <font color="blue">commercial marketing</font> of <font color="blue">competitive</font> systems for <font color="blue">cervical cancer</font> screening,     treatment for excessive menstrual bleeding, <font color="blue">breast cancer</font>, or malignant     brain  <font color="blue">tumors could</font> have a material adverse effect on our business and     financial  condition</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">compete <font color="blue">effectively</font> against</font>     existing  and  future  <font color="blue">competitors</font> and existing and <font color="blue">future <font color="blue">alternative</font></font>     <font color="blue">treatments</font>, our <font color="blue">sales could decline</font> and our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>The  success  of  our  business  <font color="blue">depends on</font> our ability to protect our     <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">combination</font> of patents, trade secrets, copyrights, trademarks     and  <font color="blue">confidentiality</font>  <font color="blue">agreements</font>  to protect our products’ proprietary     <font color="blue">technology</font>, rights and know-how</td>
    </tr>
    <tr>
      <td>We also are the <font color="blue">exclusive licensee</font> of     <font color="blue">certain patented <font color="blue">technology</font></font> for use in the field of cytology related to the     <font color="blue">ThinPrep System</font>, in the field of <font color="blue"><font color="blue">breast cancer</font> detection</font> and treatment     related  to  the  FirstCyte  Breast  Test  and in the treatment of any     <font color="blue">proliferative disease</font> relating to our <font color="blue">GliaSite System</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [41]Table of <font color="blue">Contents         </font>With our <font color="blue"><font color="blue">acquisition</font>s</font> in March 2004 and 2005, we acquired all of Novacept’s     and Proxima’s <font color="blue"><font color="blue">intellectual property</font> rights</font>, respectively, including those     <font color="blue">with respect</font> to the NovaSure System, the <font color="blue"><font color="blue">MammoSite System</font> </font>and the GliaSite     System</td>
    </tr>
    <tr>
      <td>However, the medical device industry in general, and the <font color="blue">therapeutic</font>     use of devices employing radiofrequency energy, such as the NovaSure System,     in particular, have been subject to extensive <font color="blue">litigation</font> and <font color="blue">administrative</font>     <font color="blue">proceedings</font> regarding patents and other <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>If we fail to protect, defend and maintain the <font color="blue"><font color="blue">intellectual property</font> rights</font>     <font color="blue">with respect</font> to any of our products or if we are subject to a successful     third-party  claim  of <font color="blue">infringement</font>, the <font color="blue">competitive</font> position of these     <font color="blue">products could</font> be impaired</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">infringement</font>, interference and     other <font color="blue">intellectual property</font> claims and <font color="blue">proceedings</font>, with or <font color="blue">without merit</font>,     are expensive and time-consuming to litigate and could <font color="blue">adversely</font> affect our     business, <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>If <font color="blue">breast surgeons</font>, <font color="blue">radiation oncologists</font> and patients do not adopt the     <font color="blue"><font color="blue">MammoSite System</font> </font>as a <font color="blue">preferred treatment</font> for early-stage <font color="blue">breast cancer</font>, the     <font color="blue">intended benefits</font> of our <font color="blue">acquisition</font> of Proxima may not be realized and the     <font color="blue">market price</font> of our <font color="blue">common stock could decline</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">primary product</font> acquired as a result of our <font color="blue">acquisition</font> of Proxima is     the <font color="blue">MammoSite System</font>, which is used to treat early-stage <font color="blue">breast cancer</font></td>
    </tr>
    <tr>
      <td>The     MammoSite  System is <font color="blue">supported by only four years</font> of patient follow-up     studies  from  the  initial 43-patient study that was designed to gain     clearance from the FDA and the one-year follow-up study from a 1cmam600-patient     <font color="blue">registry following</font> the FDA clearance</td>
    </tr>
    <tr>
      <td>We <font color="blue">could discover</font> that the results of     these <font color="blue">clinical trials</font> are not <font color="blue">indicative</font> of results experienced in the     <font color="blue">market over</font> time</td>
    </tr>
    <tr>
      <td>Furthermore, some of the <font color="blue">existing data</font> has been produced     in studies that involve <font color="blue">relatively</font> small <font color="blue">patient groups</font>, and <font color="blue">such data may</font>     not be reproduced in <font color="blue">wider patient populations</font></td>
    </tr>
    <tr>
      <td>Currently, <font color="blue">with respect</font> to     our <font color="blue">MammoSite System</font>, we are <font color="blue">competing against <font color="blue">breast cancer</font> treatment using</font>     external beam radiation, which has longer-term data on patient outcome</td>
    </tr>
    <tr>
      <td>We may have <font color="blue"><font color="blue">difficult</font>y gaining further acceptance</font> of the <font color="blue"><font color="blue">MammoSite System</font> </font>    among <font color="blue">breast surgeons</font>, <font color="blue">radiation oncologists</font> and patients for a number of     reasons including:           •   the presence of <font color="blue">competing products</font> sold by companies with longer     operating histories, more <font color="blue">recognizable names</font> and more established     <font color="blue">distribution</font> networks;           •   the <font color="blue">introduction</font> or existence of <font color="blue">competing products</font> or <font color="blue">technologies</font>     that may be more effective, safer or easier to use than the MammoSite     System;           •   the results of long-term clinical studies relating to the     <font color="blue">effectiveness</font> of the <font color="blue">MammoSite System</font>;           •   the <font color="blue">availability</font> of <font color="blue">alternative</font> <font color="blue">treatments</font> or procedures that provide     comparable levels of <font color="blue">improvement</font> in <font color="blue">breast cancer</font> treatment at a lower cost     than the <font color="blue">MammoSite System</font>;           •   <font color="blue">breast surgeons</font>, <font color="blue">radiation oncologists</font> and <font color="blue">patient perceptions</font> of the     <font color="blue"><font color="blue">MammoSite System</font> </font>as compared to other <font color="blue">treatments</font> for <font color="blue">breast cancer</font>; and           •   the continued <font color="blue">availability</font> of satisfactory <font color="blue">reimbursement</font> from     <font color="blue">healthcare payors</font> for <font color="blue">breast cancer</font> treatment procedures</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">continued recommendation</font> and support for the use of the     <font color="blue"><font color="blue">MammoSite System</font> </font><font color="blue">by influential <font color="blue">breast surgeons</font></font> and <font color="blue">radiation oncologists</font>     and <font color="blue">treatment centers</font> are essential for <font color="blue">widespread <font color="blue">market acceptance</font></font></td>
    </tr>
    <tr>
      <td>If the     MammoSite  System  does not continue to receive support from these key     <font color="blue">constituencies</font>,  or if longer-term data does not <font color="blue"><font color="blue">demonstrate</font> continued</font>     support for the <font color="blue">clinical efficacy</font> of the <font color="blue">MammoSite System</font>, <font color="blue">breast surgeons</font>     and <font color="blue">radiation oncologists</font> may not use, and hospitals and <font color="blue">outpatient surgery</font>     <font color="blue">centers may</font> not purchase, the <font color="blue">MammoSite System</font></td>
    </tr>
    <tr>
      <td>If this occurs, the intended     benefits  of  the <font color="blue">acquisition</font>, such as increased net sales, may not be     realized and the <font color="blue">market price</font> of our <font color="blue">common stock could decline</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [42]Table of <font color="blue">Contents         </font>Current  levels  of  growth in the market for <font color="blue">new endometrial ablation</font>     procedures for the treatment of <font color="blue">excessive menstrual bleeding may</font> not be     <font color="blue">indicative</font> of <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>Demand for newly introduced <font color="blue">technologies</font> or <font color="blue">treatments</font> can initially be     <font color="blue">exaggerated</font> as supply increases to meet pre-existing demand</td>
    </tr>
    <tr>
      <td>However, once     the pre-existing demand is met, growth in the <font color="blue">market may abruptly stop</font> or     <font color="blue">significant</font>ly slow</td>
    </tr>
    <tr>
      <td>We believe that some of the <font color="blue">current growth</font> in the market     for <font color="blue">new endometrial ablation</font> procedures may be the result of a considerable     pre-existing unmet demand for products of this nature</td>
    </tr>
    <tr>
      <td>We cannot determine     what  portion  of  Novacept’s <font color="blue">historical sales</font> is <font color="blue">attributable</font> to this     pre-existing demand, nor can we predict when, or at what rate, this demand     may  stop  or decline in growth</td>
    </tr>
    <tr>
      <td>If the demand for <font color="blue">treatments</font> like the     <font color="blue">NovaSure System </font>were to <font color="blue">stop abruptly</font> or begin to decline, our operating     results and <font color="blue">profitability could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot accurately predict</font> the <font color="blue">rates at which women will undergo</font> the     NovaSure procedure</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the market for <font color="blue">endometrial ablation products will</font>     continue to develop in the future or that the <font color="blue">new endometrial ablation</font>     procedures, including the NovaSure procedure, will continue to experience     similar  or <font color="blue">greater rates</font> of use</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be     successful in continuing to <font color="blue">attract physicians</font> and women to use the NovaSure     System, or whether or not evolving trends in the treatment of excessive     menstrual  bleeding  will favor <font color="blue">new endometrial ablation</font> procedures as     compared to <font color="blue">traditional approaches</font></td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> the <font color="blue">continued <font color="blue">market acceptance</font></font> of our ThinPrep     System products and their cost</td>
    </tr>
    <tr>
      <td>Our success and growth <font color="blue">depends on</font> the <font color="blue">continued <font color="blue">market acceptance</font></font> of our     ThinPrep  System  and ThinPrep Imaging System, including any follow-on     <font color="blue">applications</font>  of ThinPrep <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">laboratory cost</font> of using the     <font color="blue">ThinPrep System</font> and ThinPrep Imaging System for <font color="blue">cervical cancer</font> screening,     both together and <font color="blue">individually</font>, is higher than that of a <font color="blue">conventional</font> Pap     smear and, we believe, competing liquid-based slide preparation systems</td>
    </tr>
    <tr>
      <td>Due     in part to increased <font color="blue">competitive</font> pressures in the <font color="blue">healthcare industry</font> to     <font color="blue">reduce costs</font>, our ability to <font color="blue">gain <font color="blue">market acceptance</font></font> of the <font color="blue">ThinPrep System</font>     and follow-on products <font color="blue">depends on</font> our ability to <font color="blue">demonstrate</font> that the higher     cost of using the <font color="blue">ThinPrep System</font> is offset by (1) a reduction in costs     often associated with <font color="blue">conventional</font> Pap smears or competing liquid-based     slide preparation systems, such as inaccurate diagnoses and the need for     repeat Pap smears, as well as (2) the ability to use our <font color="blue">ThinPrep System</font> for     <font color="blue">additional</font> testing <font color="blue">applications</font>, such as testing for the HPV, Chlamydia     <font color="blue">trachomatis</font> and <font color="blue">Neisseria </font>gonorrhea</td>
    </tr>
    <tr>
      <td>In particular, for both the ThinPrep     Imaging System and the FirstCyte Breast Test, we need to <font color="blue">convince healthcare</font>     providers, insurance companies and other third-party payors, and clinical     <font color="blue">laboratories</font>  of the <font color="blue">clinical benefits</font> and cost-<font color="blue">effectiveness</font> of these     products</td>
    </tr>
    <tr>
      <td>For the FirstCyte Breast Test, we await the results of an outcome     study  to support <font color="blue">additional</font> claims to <font color="blue">drive <font color="blue">market acceptance</font></font> of this     product and its cost</td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> our ability to <font color="blue">manage <font color="blue">growth <font color="blue">effectively</font></font></font></td>
    </tr>
    <tr>
      <td>The scope of our <font color="blue">operations</font> and <font color="blue">facilities</font>, the number of our employees and     the <font color="blue">geographic area</font> of our <font color="blue">operations</font> have <font color="blue">grown rapidly</font></td>
    </tr>
    <tr>
      <td>If we are not able     to manage our <font color="blue">growth <font color="blue">effectively</font></font>, our business and <font color="blue">financial condition</font> will     <font color="blue">materially</font> suffer</td>
    </tr>
    <tr>
      <td>Our growth may <font color="blue">significant</font>ly strain our managerial,     operational  and <font color="blue">financial resources</font> and systems</td>
    </tr>
    <tr>
      <td>To manage our growth     <font color="blue">effectively</font>, we will have to continue to implement and improve <font color="blue">additional</font>     <font color="blue">management</font> and <font color="blue">financial systems</font> and controls, and to <font color="blue">effectively</font> expand,     train and manage our <font color="blue">employee base</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> integrate future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">continually</font> explore opportunities</font> to acquire related <font color="blue">businesses</font>, some of     <font color="blue">which could</font> be material to us</td>
    </tr>
    <tr>
      <td>Our ability to continue to <font color="blue">grow may depend</font>     upon  identifying  and  <font color="blue">successfully</font>  acquiring  <font color="blue">attractive companies</font>,     <font color="blue">effectively</font> integrating such companies, achieving <font color="blue">cost efficiencies</font> and     managing these <font color="blue">businesses</font> as part of our company</td>
    </tr>
    <tr>
      <td>We may not be able to     <font color="blue">effectively</font>  integrate  acquired  companies and <font color="blue">successfully</font> implement     appropriate operational, financial and <font color="blue">management</font> systems and controls to     achieve the benefits expected to result from these <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Our effort     to integrate these <font color="blue">businesses</font> could be <font color="blue">affected by</font> a number of factors     beyond  our control, such as <font color="blue">regulatory</font> <font color="blue">development</font>s, general economic     conditions, increased competition, the loss of customers resulting from the     <font color="blue"><font color="blue">acquisition</font>s</font> and the <font color="blue">assumption</font> of <font color="blue">unknown liabilities</font></td>
    </tr>
    <tr>
      <td>In addition, the     process of integrating these <font color="blue">businesses</font> could cause an <font color="blue">interruption</font> of, or     loss of momentum in, the <font color="blue">activities</font> of our existing business and the loss of     <font color="blue">key personnel</font> and customers</td>
    </tr>
    <tr>
      <td>The diversion of <font color="blue">management</font>’s attention and                                           20     ______________________________________________________________________    [43]Table of <font color="blue">Contents         </font>any delays or <font color="blue"><font color="blue">difficult</font>ies</font> <font color="blue">encountered</font> in <font color="blue">connection</font> with the <font color="blue">integration</font> of     these <font color="blue">businesses</font> could <font color="blue">negatively</font> impact our business if any of the above     <font color="blue">adverse effects</font> were to occur</td>
    </tr>
    <tr>
      <td>Further, the benefits that we anticipate from     any future <font color="blue"><font color="blue">acquisition</font>s</font> may not develop</td>
    </tr>
    <tr>
      <td>Future  <font color="blue"><font color="blue">acquisition</font>s</font>  may  also harm our operating results, dilute our     <font color="blue">stockholders</font>’ equity and create other financial <font color="blue"><font color="blue">difficult</font>ies</font> for us</td>
    </tr>
    <tr>
      <td>We may in the future pursue <font color="blue"><font color="blue">acquisition</font>s</font> that we believe <font color="blue">could provide us</font>     with new <font color="blue">technologies</font>, products or <font color="blue">service offerings</font>, or <font color="blue">enable us</font> to obtain     other <font color="blue">competitive</font> advantages</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">by us may involve</font> some or all of the <font color="blue">following financial risks</font>:           •   use of <font color="blue">significant</font> amounts of cash;           •   <font color="blue">potential dilutive issuances</font> of <font color="blue">equity securities</font>;           •   incurrence of debt or <font color="blue">amortization expenses</font> related to certain     <font color="blue">intangible assets</font>; and           •   <font color="blue">future impairment charges</font> related to <font color="blue">diminished fair value</font> of     <font color="blue">businesses</font> acquired as compared to the price we pay for them</td>
    </tr>
    <tr>
      <td>We may not be successful in overcoming the <font color="blue">risks described</font> above or any     other problems associated with future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Any of these risks and     problems  could  <font color="blue">materially</font> harm our business, prospects and financial     condition</td>
    </tr>
    <tr>
      <td>Additionally, we <font color="blue">cannot guarantee</font> that any companies we may     acquire will achieve anticipated revenues or operating results</td>
    </tr>
    <tr>
      <td>We may be subject to the risk of <font color="blue">product <font color="blue">liability</font></font> claims relating to our     products</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of the <font color="blue">technology</font> employed, surgical procedures involve risk of     <font color="blue">complications</font> and companies that produce <font color="blue">medical devices</font> for use in surgical     procedures are subject to risk of <font color="blue">product <font color="blue">liability</font></font> <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>We could     become a party to legal <font color="blue">proceedings</font> involving injuries to patients that     occurred when one of our products is used</td>
    </tr>
    <tr>
      <td>We <font color="blue">will vigorously defend against</font>     any <font color="blue">product <font color="blue">liability</font></font> claims that may arise related to any of our products</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that any <font color="blue">defense against</font> alleged claims     will be successful</td>
    </tr>
    <tr>
      <td>If one of our products is found to have caused or <font color="blue">contributed</font> to injuries or     deaths, we could be held liable for substantial damages</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font>     insurance is in place for all of our products</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you     that  <font color="blue">available insurance will</font> be sufficient to <font color="blue">cover damages from</font> any     <font color="blue">possible future</font> claims</td>
    </tr>
    <tr>
      <td>In addition, claims could <font color="blue">adversely</font> affect the     reputation  of the related product, <font color="blue">which could</font> damage its <font color="blue">competitive</font>     position in the market</td>
    </tr>
    <tr>
      <td>The sale and use of one of our <font color="blue">diagnostic products</font>     <font color="blue"><font color="blue">could also</font> lead</font> to the filing of <font color="blue">product <font color="blue">liability</font></font> claims if someone were to     allege that one of our <font color="blue">products contained</font> a design or <font color="blue"><font color="blue">manufacturing</font> defect</font>     that resulted in the failure to detect a disorder for which it was being     used to screen or caused injuries to a patient</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product <font color="blue">liability</font></font> claim     brought against us, with or <font color="blue">without merit</font>, could result in the increase of     our <font color="blue">product <font color="blue">liability</font></font> insurance rates or the <font color="blue">inability</font> to secure <font color="blue">additional</font>     coverage in the future</td>
    </tr>
    <tr>
      <td>Also, even a meritless or <font color="blue">unsuccessful product</font>     <font color="blue">liability</font> claim could be time consuming and expensive to defend, <font color="blue">which could</font>     result in a diversion of <font color="blue">management</font>’s attention from our business and could     <font color="blue">adversely</font> affect the perceived safety and efficacy of our products, as well     as our <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>Our quarterly operating results <font color="blue">may fluctuate</font></td>
    </tr>
    <tr>
      <td>Our  operating  results have fluctuated <font color="blue">significant</font>ly in the past on a     quarterly  basis</td>
    </tr>
    <tr>
      <td>We  expect that our operating results <font color="blue">may fluctuate</font>     <font color="blue">significant</font>ly from quarter to quarter and we may experience losses in the     <font color="blue">future depending on</font> a number of factors, including the extent to which our     <font color="blue">products continue</font> to gain or maintain <font color="blue">market acceptance</font>, the rate and size     of  <font color="blue">expenditures</font>  <font color="blue">incurred as</font> we expand our domestic and establish our     <font color="blue">international</font> sales and <font color="blue">distribution</font> networks, the timing and level of     <font color="blue">reimbursement</font> for our products by third-party payors, and other factors,     many of which are outside our control</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [44]Table of <font color="blue">Contents         </font>We  currently have limited <font color="blue">international</font> sales <font color="blue">capabilities</font> and cannot     <font color="blue">guarantee success</font> in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">commenced sales</font> in <font color="blue">countries outside</font> <font color="blue">the <font color="blue">United States </font></font>in 1998,     only a small percentage of our sales to date have been to <font color="blue">international</font>     markets</td>
    </tr>
    <tr>
      <td>If we fail to increase <font color="blue">international</font> sales, our business and     <font color="blue">financial condition</font> may suffer <font color="blue">materially</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that we will     <font color="blue">successfully</font> develop <font color="blue">international</font> sales channels or <font color="blue">capabilities</font> that will     <font color="blue">enable us</font> to generate <font color="blue">significant</font> revenue from <font color="blue">international</font> sales</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>though we have established <font color="blue">international</font> sales <font color="blue">capabilities</font>, we may not be     able to obtain favorable third-party <font color="blue">reimbursement</font>s and required <font color="blue">regulatory</font>     approvals  in  <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>While we believe we have developed a     comprehensive <font color="blue">international</font> patent filing strategy, we have not secured     patents in all <font color="blue">foreign countries</font> which we <font color="blue">currently sell</font> or plan to sell our     products</td>
    </tr>
    <tr>
      <td>In some cases our ability to <font color="blue">pursue patents</font> in <font color="blue">certain countries</font>     has  lapsed</td>
    </tr>
    <tr>
      <td>In those countries where we do have <font color="blue">patents covering</font> our     products, we <font color="blue">cannot guarantee</font> that <font color="blue">such patents may</font> be <font color="blue">successfully</font> enforced     <font color="blue">against infringing products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also face <font color="blue">difficult</font>y</font> and <font color="blue">added expense</font>     in <font color="blue">complying with</font> the US and <font color="blue">international</font> <font color="blue">regulations</font> applicable to the     sale and marketing of our products <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> staff</td>
    </tr>
    <tr>
      <td>Loss of our <font color="blue">key personnel</font> would likely impede <font color="blue">achievement</font> of our research     and <font color="blue">development</font>, operational, or strategic <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>To be successful, we     must retain <font color="blue">key employees</font> and attract <font color="blue">additional</font> qualified employees</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on single source</font> or limited <font color="blue">source suppliers could harm</font> our     business</td>
    </tr>
    <tr>
      <td>We currently obtain <font color="blue">certain <font color="blue">key <font color="blue">components</font></font></font> of our products, including the     <font color="blue">proprietary filter</font> material and <font color="blue">microscope slides used</font> in the ThinPrep Pap     Test, radioisotopes, certain balloons and other items used in the design and     <font color="blue">manufacture</font> of the <font color="blue"><font color="blue">MammoSite System</font> </font>and the Iotrex <font color="blue">liquid isotope used with</font>     the <font color="blue">GliaSite System</font>, from single or a limited number of <font color="blue">sources due</font> to     <font color="blue">technology</font>,  <font color="blue">availability</font>,  price,  quality  and other <font color="blue">considerations</font></td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">NovaSure System </font><font color="blue">utilizes several <font color="blue">components</font></font> that may     become obsolete or no longer be <font color="blue">manufacture</font>d</td>
    </tr>
    <tr>
      <td>We attempt to mitigate these     risks by working <font color="blue">closely with key suppliers</font> regarding our supply needs and     we have <font color="blue">qualified backup vendors</font> for several of our <font color="blue">key <font color="blue">components</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we believe that <font color="blue">alternative</font> sources for these <font color="blue">components</font> are available, a     supply <font color="blue">interruption</font> could harm our ability to <font color="blue">manufacture</font> our <font color="blue">products until</font>     a new source of supply is identified and qualified</td>
    </tr>
    <tr>
      <td>Switching <font color="blue">components</font> may     require  product  redesign  and  submission to the FDA of a pre-market     supplement or possibly a separate pre-market approval, either of <font color="blue">which could</font>     <font color="blue">significant</font>ly  <font color="blue">delay production</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain sufficient     quantities  of  these  <font color="blue">components</font>  that meet our quality and technical     <font color="blue"><font color="blue">requirements</font> at reasonable prices</font> and in a timely manner, we will not be     able to <font color="blue">manufacture</font> and sell our <font color="blue">products on</font> a timely and cost-<font color="blue">competitive</font>     basis,  which  would  <font color="blue">materially</font> and <font color="blue">adversely</font> affect our business and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our lack of redundant <font color="blue">manufacturing</font> <font color="blue">capabilities</font> could harm our business</td>
    </tr>
    <tr>
      <td>We assemble all of our ThinPrep Processors, the ThinPrep Imaging System, the     <font color="blue">FirstCyte Breast Test </font>and the single-use disposable devices in the NovaSure     System</td>
    </tr>
    <tr>
      <td>In addition, we contract with third-parties to <font color="blue">manufacture</font> our     <font color="blue"><font color="blue">MammoSite System</font> </font>and <font color="blue">GliaSite System</font></td>
    </tr>
    <tr>
      <td>We have established a <font color="blue">certain level</font> of     <font color="blue">site redundancy on</font> our <font color="blue">core products</font>, or have developed <font color="blue">alternate sources</font></td>
    </tr>
    <tr>
      <td>While we have made <font color="blue">significant</font> efforts to safeguard these <font color="blue">core <font color="blue">manufacturing</font></font>     processes,  the  loss  of  any  of  these  <font color="blue">facilities</font> would impede our     <font color="blue">manufacturing</font> and sales efforts, which would <font color="blue">materially</font> and <font color="blue">adversely</font> affect     our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Because a component of the <font color="blue">NovaSure System </font>is <font color="blue">manufacture</font>d in Costa Rica, we     will be subject to the political and <font color="blue">economic risks</font> of doing business there</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that the political, labor and <font color="blue">economic climate</font> in Costa     Rica  will  <font color="blue">remain sufficiently stable</font> for un<font color="blue">interrupted</font> <font color="blue">manufacturing</font>     <font color="blue">operations</font> in that country</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> relating to the <font color="blue">NovaSure System </font>    could be <font color="blue">adversely</font> <font color="blue">affected by</font> political unrest and we <font color="blue">could also</font> be harmed     by strikes and other <font color="blue">labor <font color="blue">disruptions</font></font></td>
    </tr>
    <tr>
      <td>Any of these events could result in     increased costs or in <font color="blue">disruptions</font> of supply of the NovaSure disposable     devices, or any other product or component we may elect to <font color="blue">manufacture</font> in     <font color="blue">Costa Rica </font>in the future, <font color="blue">which could</font> harm our business, <font color="blue">financial condition</font>     and operating results</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [45]Table of <font color="blue">Contents         </font>We are subject to numerous FDA laws and <font color="blue">regulations</font>, and non-compliance with     such laws, as well as changes in such laws or <font color="blue">future interpretations</font> of such     laws, could cause us to incur <font color="blue">significant</font> compliance costs and/or subject us     to <font color="blue">significant</font> civil and <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with these     <font color="blue">requirements</font> imposes <font color="blue">significant</font> expenses on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, we could be subject to a wide range of     civil and <font color="blue">criminal enforcement sanctions</font>, our <font color="blue">promotional practices may</font> be     restricted, and our marketed <font color="blue">products could</font> be subject to recall or loss of     FDA marketing claim approval</td>
    </tr>
    <tr>
      <td>We  cannot  guarantee  we will obtain or maintain necessary <font color="blue">regulatory</font>     approvals for our products</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">regulatory</font> approval process can be expensive, lengthy and uncertain     for <font color="blue">both original</font> and <font color="blue">supplemental approvals</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that     we will be able to obtain necessary <font color="blue">regulatory</font> <font color="blue">clearances</font> or approvals for     any <font color="blue">proposed future products</font> or <font color="blue"><font color="blue">modification</font>s</font> of <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>The     failure to obtain <font color="blue">clearances</font> or approvals, loss of <font color="blue">previously</font> received     <font color="blue">clearances</font> or approvals, or a failure to <font color="blue"><font color="blue">comply with</font> existing</font> or future     <font color="blue">regulatory</font>  <font color="blue">requirements</font>,  would have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">modification</font>s</font> to a device that has received a pre-market approval that     affect its safety or <font color="blue">effectiveness</font> require a pre-market approval supplement     or possibly a separate pre-market approval, either of which is likely to be     time-consuming, expensive and uncertain to obtain</td>
    </tr>
    <tr>
      <td>The FDA requires the     device <font color="blue">manufacture</font>r to make and document its <font color="blue">determination whether</font> or not a     pre-market approval or supplement is required, but the FDA can review the     <font color="blue">manufacture</font>r’s decision</td>
    </tr>
    <tr>
      <td>Before the <font color="blue">acquisition</font>, Novacept <font color="blue">modified various</font>     aspects of the <font color="blue">NovaSure System </font>and filed and received approval for one     pre-market supplement <font color="blue">with respect</font> to some of the changes in the design of     and <font color="blue">manufacturing</font> process for its disposable device</td>
    </tr>
    <tr>
      <td>However, the FDA may     not <font color="blue">agree with</font> Novacept’s <font color="blue">decisions</font> not to <font color="blue">seek supplements</font> or <font color="blue">new approvals</font>     for the other device <font color="blue"><font color="blue">modification</font>s</font> or with our <font color="blue">decisions</font> regarding any     future device <font color="blue"><font color="blue">modification</font>s</font> for the <font color="blue">NovaSure System </font>or any of our other     product  lines</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires us to seek one or more pre-market     approval supplements or new pre-market approvals for any <font color="blue">modification</font> to a     <font color="blue">previously</font> approved device, we may be required to <font color="blue">cease marketing</font> or to     recall the modified device until we obtain approval, and we may be subject     to <font color="blue">significant</font> criminal and/or civic sanctions, including but not limited     to, <font color="blue">regulatory</font> fines or penalties</td>
    </tr>
    <tr>
      <td>If we or our contract <font color="blue">manufacture</font>rs fail to <font color="blue">comply with</font> the FDA’s Quality     System Regulation, <font color="blue">manufacturing</font> <font color="blue">operations</font> could be <font color="blue">interrupted</font>, and our     <font color="blue">product sales</font> and operating results could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our design and <font color="blue">manufacturing</font> processes are required to <font color="blue">comply with</font> the     FDA’s  Quality  System  Regulation,  which  covers  the procedures and     <font color="blue">documentation</font>  of  the  design,  testing, production, control, quality     assurance, labeling, packaging, sterilization, storage and shipping of our     devices</td>
    </tr>
    <tr>
      <td>The FDA enforces its <font color="blue">Quality System Regulation </font><font color="blue">through unannounced</font>     <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>If one of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> fails an inspection,     <font color="blue">operations</font> and <font color="blue">manufacturing</font> could be disrupted</td>
    </tr>
    <tr>
      <td>Failure to take adequate     and timely corrective action in response to an <font color="blue">adverse inspection could</font>     force  a shutdown of these <font color="blue">manufacturing</font> <font color="blue">operations</font> or a recall of the     product</td>
    </tr>
    <tr>
      <td>If we shut down <font color="blue">manufacturing</font> <font color="blue">operations</font> or recall our products, we     <font color="blue">may lose customers</font> and experience a decline in our revenues</td>
    </tr>
    <tr>
      <td>Our products may be subject to recalls even after receiving FDA clearance or     approval, and if a recall occurs, the reputation of our products and our     operating results could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The  FDA  and  similar <font color="blue">governmental</font> bodies in other countries have the     authority to require the recall of our products in the event of material     <font color="blue">deficiencies</font> or defects in design or <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">government mandated</font> or     voluntary  <font color="blue">recall by us could</font> occur as a result of component failures,     <font color="blue">manufacturing</font> errors or <font color="blue">design defects</font>, including defects in labeling</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">recall could harm</font> the reputation of our products and <font color="blue">adversely</font> affect our     <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">activities</font> may subject us to risks under federal and state laws     prohibiting “kickbacks” and false or <font color="blue">fraudulent</font> claims</td>
    </tr>
    <tr>
      <td>We are subject to the provisions of a <font color="blue">federal law commonly known as</font> the     Medicare/Medicaid anti-kickback law, and several similar state laws, which     <font color="blue">prohibit payments intended</font> to <font color="blue">induce physicians</font> or <font color="blue">others either</font> to refer                                           23     ______________________________________________________________________    [46]Table of <font color="blue">Contents         </font>patients  or to acquire or arrange for or recommend the <font color="blue">acquisition</font> of     <font color="blue">healthcare products</font> or services</td>
    </tr>
    <tr>
      <td>While the federal law applies only to     referrals, products or services for which payment may be made by a federal     healthcare program, state laws often apply <font color="blue">regardless</font> of whether federal     funds may be involved</td>
    </tr>
    <tr>
      <td>These <font color="blue">laws constrain</font> the sales, marketing and other     promotional <font color="blue">activities</font> of <font color="blue">manufacture</font>rs of <font color="blue">medical devices</font>, such as us, by     limiting the kinds of <font color="blue">financial arrangements</font>, including sales programs, with     hospitals,  physicians, <font color="blue">laboratories</font> and other <font color="blue">potential purchasers</font> of     <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Other federal and state <font color="blue">laws generally prohibit individuals</font>     or <font color="blue">entities from knowingly presenting</font>, or causing to be presented, claims     for <font color="blue">payment from</font> Medicare, Medicaid, or other third-party payors that are     false or <font color="blue">fraudulent</font>, or are for items or services that were not <font color="blue">provided as</font>     claimed</td>
    </tr>
    <tr>
      <td>Anti-kickback and false claims laws prescribe civil and criminal     penalties for <font color="blue">noncompliance</font> that can be substantial</td>
    </tr>
    <tr>
      <td>While we <font color="blue">continually</font>     strive to <font color="blue">comply with</font> these complex <font color="blue">requirements</font>, interpretations of the     <font color="blue">applicability</font> of these laws to <font color="blue">marketing practices</font> is <font color="blue">ever evolving</font> and even     an <font color="blue">unsuccessful challenge could</font> cause adverse publicity and be costly to     respond to, and thus could have a material adverse effect on our business,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">certificate</font> of incorporation, bylaws and <font color="blue"><font color="blue">Delaware </font>    </font><font color="blue">law may delay</font> or prevent a change in control of our company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate documents</font> and <font color="blue">Delaware </font><font color="blue">law contain provisions</font> that may enable     our board of <font color="blue">directors</font> to resist a change in control of our company</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions include:           •   a <font color="blue">staggered board</font> of <font color="blue">directors</font>;           •   <font color="blue">limitations on persons authorized</font> to call a <font color="blue">special meeting</font> of     <font color="blue">stockholders</font>;           •   the <font color="blue">authorization</font> of <font color="blue">undesignated preferred stock</font>, the terms of which     may be established and shares of which may be <font color="blue">issued without stockholder</font>     approval;           •   advance notice procedures required for <font color="blue">stockholders</font> to nominate     <font color="blue">candidates</font> for election as <font color="blue">directors</font> or to <font color="blue">bring matters</font> before an annual     meeting of <font color="blue">stockholders</font>; and           •   a <font color="blue">stockholder rights agreement</font> or “<font color="blue">poison pill</font></td>
    </tr>
    <tr>
      <td>”         In addition, we are subject to the anti-takeover provisions of Section 203     of  the  <font color="blue">Delaware </font> General  Corporation  Law, <font color="blue">which may prohibit</font> large     <font color="blue">stockholders</font>, in particular those owning 15prca or more of our outstanding     voting stock, from merging or <font color="blue">consolidating with us except under certain</font>     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>These  anti-takeover  defenses  could  discourage,  delay or prevent a     <font color="blue">transaction involving</font> a change in control of our company</td>
    </tr>
    <tr>
      <td>These provisions     could  also  discourage  <font color="blue">proxy contests</font> and make it more <font color="blue">difficult</font> for     <font color="blue">stockholders</font> to elect <font color="blue">directors</font> of their choosing and cause us to take other     corporate actions <font color="blue">stockholders</font> desire</td>
    </tr>
  </tbody>
</table>